Neurocrine Biosciences, Inc. · Healthcare
Survives a bust-sized cut to analyst growth (10 points, or half the forecast if larger), with the median analyst target at least 15% above the price and no more than one earnings-quality red flag.
At a 26.0% margin the price requires 0.6% 3y revenue CAGR against 21.0% consensus, a cushion of +21.8pt versus a 0pt correction cut. Cushion is wide and the drawdown is not the company's own; it should come out ahead of the correction. Launch story intact; unaffected.
Breaks if: the launch ramp misses the 21% consensus CAGR. We re-check this against analyst estimates every evening.
10 years, at a 26% margin analysts expect
+13.4%/yr over 10 years once faded to terminal growth
points off 3-year analyst growth
23 published targets, set before the drop
Does the profit analysts build their margin on actually arrive as cash? Measured over the last 3 annual statements filed before this test. After stock-based pay, 108% of reported profit arrived as operating cash, so the analysts' margin stands.
How much of reported profit arrived as operating cash. Below 0.8× is a red flag.
Profit not backed by cash, as a share of assets, latest year. Above 10% is a red flag.
Staff paid in shares instead of cash, which flatters margins. Above 10% is a red flag.
Dilution of each share's claim on the business. Above 3% a year is a red flag.
Non-operating gains in the latest year. Above 25% is a red flag.
After capex. Shown for context: heavy investment is not bad earnings, so it is never solved under.
From the priced-in reconstruction of Sep 3, 2026. Its figures use that day's price and free-cash-flow margin, so they can differ from the stress test above.
The price sits at the very bottom of 23 published models, rejecting the 20 bull cases that reach up to $230, which means the market is pricing a steep growth deceleration from the 21.4% just delivered down to the 6.5% the reverse-DCF requires.
Can Crenessity, Vykat XR, and Ingrezza's trajectory to $3.3B in peak sales deliver enough volume growth to break the 6.5% deceleration the price assumes, and unit volume data is wired to settle it.
What the price refuses to pay for, and the full reconstruction, on the NBIX quote page →A stress test of whether this narrative is still paid for by analyst forecasts, not a forecast that the stock will rise. The price-implied growth on its own has not predicted returns in our testing, and this list (sealed Nov 21, 2026) has not been graded yet. Cut sizes are assumptions. Not investment advice. Back to all names